Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

Targeted Oncology - ResearchHub

ResearchHub

Research, connected

Explore the graph

X

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Help Article feed Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal

Targeted Oncology

1776-2596 · Springer Science and Business Media LLC

104 verified public works

Browse all journals →

From the bench to the bedside: emerging new treatments in multiple myeloma

2007 · 0 citations

From suntan to skin cancers: molecular pathways and prevention strategies

2007 · 0 citations

Biological significance of myeloperoxidase (MPO) on green tea component, (−)-epigallocatechin-3-gallate (EGCG)-induced apoptosis: its therapeutic potential for myeloid leukemia

2007 · 0 citations

A new era in prostate cancer therapy: new targets and novel therapeutics

2007 · 0 citations

ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer

2007 · 0 citations

The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics

2007 · 0 citations

Targeted therapy in hormone refractory prostate cancer

2007 · 0 citations

Combining targeted therapies

2007 · 0 citations

Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report

2007 · 0 citations

New angiogenic agents and non-small cell lung cancer: current results and future development

2007 · 0 citations

Molecular targeted therapy for advanced hepatocellular carcinoma

2007 · 0 citations

Beyond outstanding results with VEGFR/PDGFR inhibitors in advanced hepatocellular carcinoma: can imaging help where biomarkers keep us waiting?

2007 · 0 citations

Normalization, inhibition, rarefaction?

2007 · 0 citations

Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis

2007 · 0 citations

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

2007 · 0 citations

Targeted therapy in advanced colorectal cancer, an update

2007 · 0 citations

Radioimmunotherapy (RIT) in non-Hodgkin lymphoma

2007 · 0 citations

Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment

2007 · 0 citations

VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition

2007 · 0 citations

Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient

2007 · 0 citations

Have we made progress with biological agents in metastatic colorectal cancer?

2007 · 0 citations

The value of innovation: the economics of targeted drugs for cancer

2007 · 0 citations

Targeted therapies in head and neck cancer

2007 · 0 citations

Lapatinib: a novel dual tyrosine kinase inhibitor

2007 · 0 citations

Highlights from the pharmacology and molecular mechanisms group annual meeting

2007 · 0 citations

Targeted therapy for small cell lung cancer

2007 · 0 citations

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

2007 · 0 citations

Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma

2007 · 0 citations

Author index

2007 · 0 citations

Proffered papers and posters

2007 · 0 citations

PreviousPage 2 of 4Next